The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

Asthma

1. Annualized rate of clinically significant exacerbations over the treatment period.

1. Clinical remission at 2 years (104 weeks), defined as: • No clinically significant asthma exacerbations during the first 2 years of the treatment period and • No maintenance OCS for asthma at 2 years and • Well controlled asthma based on an ACT ≥20 at 2 years and • No deterioration of lung function. Deterioration is defined as a reduction in post-BD FEV1 of more than 0 ml at 2 years compared to baseline., 2. Change from baseline in AQLQ total overall score at 2 years, in participants with baseline ACQ-5 ≥1.5., 3. Change from baseline in ACQ-5 score at 2 years, in participants with baseline ACQ-5 ≥1.5., 4. Change from baseline of post-BD FEV1 at 2 years., 5. Change from baseline of pre-BD FEV1 at 2 years.

No related papers found yet.